Medicine, Antibiotics Exports Gaining Share In US, Italian Markets: Govt Data According To The Commerce Ministry Data, India

New Delhi: With the Union government focusing on boosting domestic manufacturing of pharmaceutical products, India’s medicine and antibiotics exports have started gaining significant market share in the US.

According to the commerce ministry data, India is the third largest import source of ‘medicine put up for retail sale’ for the US. The top two are Ireland and Switzerland.

In 2023, the country exported these medicines worth $9 billion as against $7.33 billion in 2022.

With this increase in the shipments, India’s share went up to 13.1 percent in 2023 from 10.08 percent in 2022. Share of the top exporter Ireland fell to 13.85 percent in 2023 from 17.18 percent in 2022 because its sales in the US went down to $9.5 billion in 2023 from $12.5 billion in 2022.

The second biggest exporter Switzerland also saw its share decline to 13.7 percent last year from 17.4 percent in 2022.

Similarly, India has increased its share among exporters of antibiotics in the Italian market. It is ranked 10th in that market by increasing its share to 2.12 percent in 2023 from 0.96 percent in 2022.

In value terms, the country’s antibiotics exports to Italy stood at $23.34 million in 2023 as against $11.48 million in 2022.

Further, the data showed that India’s competitiveness is growing in the Magnetic Resonance Imaging (MRI) apparatus market of Germany.

In 2023, the country made a small gain by increasing its export share in Germany to 1.7 percent from 0.45 per cent in 2022.

In value terms, India exported these MRI machines worth $13.02 million last year as against $2.93 million in 2022.

India is the sixth largest exporter of MRI apparatus, whereas the UK is the leader with exports of $460 million.

“Penetrating the EU market is difficult and it is important that we have a base coming in. These reflect some efforts which are being put in terms of monitoring various markets and various commodities to see where growth can be pushed,” an official said.

Pharma and medical devices manufacturing is the priority area for the government and these two sectors were the first ones to get a Production Linked Incentive (PLI) scheme.

Related Posts

  • Pharma
  • June 18, 2025
  • 91 views
Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharmaceuticals said that the United States’ Food and Drug Administration (FDA) has concluded inspection of its manufacturing facility in Monroe, North Carolina. Glenmark Pharmaceuticals said that the United States’…

  • Pharma
  • June 18, 2025
  • 80 views
ED conducts searches across six States in drug trafficking case

The Enforcement Directorate on Tuesday conducted searches at 15 locations, including the premises of five pharmaceutical companies, across six States in connection with a drug trafficking case registered in Punjab.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

ED conducts searches across six States in drug trafficking case

ED conducts searches across six States in drug trafficking case

Gurugram: Teen dies after ‘friendly’ blow to chest; hospital role under scanner

Gurugram: Teen dies after ‘friendly’ blow to chest; hospital role under scanner

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Zydus Healthcare appoints Swati Dalal MD

Zydus Healthcare appoints Swati Dalal MD

Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda

Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda